Page 6: I'm unsure what this sentence relates/refers to: "We will convert the unit to the commonly used one when different units of measurement are employed" Page 7: Please clarify the following statement "If the data can be combined into a meta-analysis, we will include categorical data only where it can be divided into dichotomous outcomes". Which outcome data are going to be interpreted as dichotomous? What about the continuous outcomes? Page 7: Please add (i.e. up until the point of crossover) to the end of the following sentence: "As with cross-over trials, we will consider only the first phase and exclude from the analysis data obtained during the second phase." Page 7: Please define/clarify what you mean by different intervention forms, this can be taken in many different ways. Also, please detail how study quality/sample size (e.g. specific thresholds) will be used in the sensitivity analysis. Page 7: Discussion: Either remove the etc or complete the list here please "in improving breathlessness, exercise limitation, health status impairment, etc."
REVIEWER

Leona Dowman
Austin Health, Australia REVIEW RETURNED 18-Dec-2018
GENERAL COMMENTS
This is a very well written protocol. It is clear and concise. The only concern is the authors have not mentioned or appear to be aware of cochrane systematic review in non non-malignant dust-related respiratory diseases (Dale 2015) . Theis cochrane review included Dust-related respiratory diseases from either occupational or nonoccupational exposure categorising them as either dust related interstitial lung disease (Dust related ILD) such as asbestosis, silicosis, pneumoconiosis and asbestosis related pleural diseases. This review also included subgroup analysis of Dust related ILD. Dust related ILDs and pneumoconiosis are effecively the same type of disease, just different terminology. Whilst this review may still be relevant and provide additional data it is not the first systematic review to investigate the efficacy and safety of PR for patients with pneumoconiosis. This needs to be addressed in the introduction and planning of this protocol.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Reviewer Name: Arwel Jones Thank you very much for your suggestion. Your comments are valuable and useful for modifying and perfecting our papers, and have important guiding significance for our research.
PRISMA-P
The majority of this protocol has been reported in line with PRIMSA-P Checklist. However, some revisions are required. Firstly, you state N/A for the amendments section. You have actually indicated your intention to document important protocol amendments in the manuscript which would be relevant for this section. More importantly, however, there are already deviations in this manuscript to what is reported on PROSPERO. Specifically, the outcomes of your review on PROSPERO are limited to 6MWT and SGRQ whilst in the manuscript you have many other outcomes listed (and SGRQ is now a primary outcome whereby on PROSPERO it was secondary). Please clarify this in the manuscript. Also, I do not consider the information on quality assessment in the manuscript to be sufficiently detailed to satisfy the requirements of the PRISMA checklist e.g. it is not specified whether assessment for each included RCT will be done at study or outcome level or both; sensitivity analysis is proposed based on quality of studies but no detail on how studies will be stratified. I also note that you have indicated N/A for quality of the body of evidence (GRADE), which I assume you mean it is not being completed as opposed to not being relevant?
Response：
We are very sorry for our incorrect writing. We do not envisage any further amendments to this protocol. However, in case of any changes, the amendment shall be detailed out in the final report.
(Page 8)
Thank you very much for your suggestion. We have updated our protocol on PROSPERO, but the verify of the protocol will take some time. When the protocol is approved, you will see our updated protocol. According to your suggestion, the primary outcomes are changed to functional capacity and health-related quality of life, and secondary outcomes pulmonary function, symptoms and acute exacerbations. (Page 5) As for methodological quality, it will be independently assessed using the Cochrane Collaboration's tool for assessing risk of bias in RCTs. The assessment details include sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting and other sources of bias. Each domain will be assessed as 'low risk', 'high risk' or 'unclear risk' according to the description details of eligible studies. (Page 6) The quality assessment of the body of evidence is performed to determine the extent to which an estimate of effect is close to the true quantity/value; that is, it is not distorted by internal or external bias within and across studies. The assessment will be conducted by outcome of interest using the GRADE system. The quality of outcome measures will be categorized as high, moderate, low, and very low. We have made changes in the manuscript and the PRISMA checklist. (Page 8)
Title: Based on the comments below on the eligibility criteria for interventions, is this review assessing "pulmonary rehabilitation"?
Introduction
Page 3: Suggest replacing "no effective drugs or radical methods" with "limited therapeutic options" or something similar. Response：I am very sorry that we did not describe the intervention clearly. Actually, the intervention we focus on in this review is a comprehensive pulmonary rehabilitation, which is based on exercise training, including or not including health education, nutritional intervention, and psychosocial support etc. We will remove studies of some interventions (e.g. health education, nutritional intervention and psychosocial support) without the presence of exercise training. (Page 4)
Baduanjin exercise is a kind of ancient Chinese health Qigong exercise which involves training of musculoskeletal relaxation and stretching, breathing control, and mental focus at a slow pace. It is a mild-to-moderate intensity form of aerobic exercise, and consists of eight simple movements，which are support heaven with both hands, dragon sprays water with force, big bird spreads its wings, lift window to look at the moon on the left, descend to earth with force and beautiful maiden twists her waist to the right, 'Extend' shoulders to bring hands together, Dragon claws to the left (Koh 1982 , Chen 2006 . Baduanjin exercise as exercise prescription has become more and more popular, and has also been widely employed.
According to your suggestion, the comparison of "PR with other treatments" has been removed in the comparisons investigated. (Page 5)
Page 5: Outcomes: I accept this may be too late for your protocol, but I would have suggested that change of primary outcomes to functional capacity and health-related quality of life would maximise use of the available evidence. It is conceivable that there will be studies who choose other outcomes measures than 6MWD (e.g.ISWT) and SGRQ (e.g. CRQ) for these domains. Same for mMRC, whereby symptoms may have been a better term to also have the capacity to include data on other measures (e.g. CAT). The following outcomes require clarification/further definition: Pulmonary function, acute exacerbations and effective rate.
Response：Thank you very much for your suggestion. We have already modified outcomes both in the manuscript and on PROSPERO according to your suggestion. The primary outcome measures were functional capacity and health-related quality of life, as measured by Six-minute walk distance (6MWD), St. George's Respiratory Questionnaire (SGRQ). The secondary outcomes measures were pulmonary function, symptoms and acute exacerbations, as measured by forced vital capacity (FVC), Since the definition of "effective rate" in the literatures is generally unclear, and it is not convincing in the evaluation of outcome, we remove this outcome. As for acute exacerbations, we mainly focus on the frequency of acute exacerbation of the condition. With regard to pulmonary function, the indicators we will mainly collect for analysis are forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1). Study selection: Page 5: "The review authors will record all studies that do not meet the inclusion criteria and provide the rationale for their exclusion." I assume here you mean reasons for exclusion for any full texts as opposed to all studies?
Response：I am sorry that the process of study selection is not clearly described. When we preliminary screen out the potentially eligible studies, we will carefully read the full text of potentially eligible studies. Then we also will record all full texts that do not meet the inclusion criteria and provide the rationale for their exclusion. (Page 6) Page 6: Data extraction and management: "When standard deviations (SDs) of the change of included studies are missing, we will substitute for them the mean SD of other included studies." Please provide justification/supporting reference for this approach. The following also seems like a lossed opportunity "We will exclude from the analysis studies in which only medians and percentiles are available and there are no means of calculating mean change scores". In addition, I query whether you would also come across studies of a mixed population (i.e. pneumoconoiosis and other lung diseases). Have the authors considered this and how you would manage the data?
Response：Thank you very much for your suggestion. The adjustment method of missing data is based on the relevant reference published in Cochrane Database of Systematic (Mccarthy 2015), where the effect of pulmonary rehabilitation on chronic obstructive pulmonary disease was investigated. We have provided supporting reference in the manuscript. (Page 6)
We will exclude studies including participants with complications, such as pulmonary heart disease, tuberculosis, and chronic pulmonary heart disease. (Page 4)
Page 6: Quality assessment and analysis: As mentioned above, please provide further detail on the risk of bias assessment (i.e. at study or outcome level or both). Please indicate if you are using all domains of the risk of bias tool.
Response：Thank you very much for your suggestion. As for methodological quality, it will be independently assessed using the Cochrane Collaboration's tool for assessing risk of bias in RCTs. The assessment details include sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting and other sources of bias. Each domain will be assessed as 'low risk', 'high risk' or 'unclear risk' according to the description details of eligible studies. Two review authors (J-JW and X-LL) will complete the data extraction and score each study, with a third review author (H-LZ) acting as an arbiter. We will summarize risk of bias and settle differences in author interpretation of data through discussion. We have made changes in the manuscript. (Page 6-7)
Page 6: I'm unsure what this sentence relates/refers to: "We will convert the unit to the commonly used one when different units of measurement are employed"
Response：Thank you very much for your suggestion. In order to combine the effect amount, we will convert the unit of measurement into a common unit accordingly. For example, we will convert the "month" or "year" into "weeks". (Page 7)
Page 7: Please clarify the following statement "If the data can be combined into a meta-analysis, we will include categorical data only where it can be divided into dichotomous outcomes". Which outcome data are going to be interpreted as dichotomous? What about the continuous outcomes?
Response：Since the definition of "effective rate" in the literatures is generally unclear, and it is not convincing in the evaluation of outcome, we remove this outcome. Then all outcomes are continuous outcomes. We have re-written this part. For continuous data, we will present the effect using mean differences (MD) with 95% CIs. We have made some changes in the data analysis section in the manuscript. (Page 7)
Page 7: Please add (i.e. up until the point of crossover) to the end of the following sentence: "As with cross-over trials, we will consider only the first phase and exclude from the analysis data obtained during the second phase."
Response：Thank you very much for your suggestion. We have added the description in the manuscript. (Page 7)
Page 7: Please define/clarify what you mean by different intervention forms, this can be taken in many different ways. Also, please detail how study quality/sample size (e.g. specific thresholds) will be used in the sensitivity analysis.
Response：Thank you very much for your suggestion. Different intervention forms refer to whether exercise training is combined with other rehabilitation measures, such as health education, nutritional intervention, psychosocial support. We will exclude studies one by one and comparing the results in the sensitivity analysis. Special thanks to you for your good comments.
Reviewer: 2
Reviewer Name: Leona Dowman Thank you very much for your suggestion. Your comments are valuable and useful for modifying and perfecting our papers, and have important guiding significance for our research.
Please leave your comments for the authors below This is a very well written protocol. It is clear and concise. The only concern is the authors have not mentioned or appear to be aware of cochrane systematic review in non non-malignant dust-related respiratory diseases (Dale 2015) . The cochrane review included Dust-related respiratory diseases from either occupational or non-occupational exposure categorising them as either dust related interstitial lung disease (Dust related ILD) such as asbestosis, silicosis, pneumoconiosis and asbestosis related pleural diseases. This review also included subgroup analysis of Dust related ILD. Dust related ILDs and pneumoconiosis are effecively the same type of disease, just different terminology. Whilst this review may still be relevant and provide additional data it is not the first systematic review to investigate the efficacy and safety of PR for patients with pneumoconiosis. This needs to be addressed in the introduction and planning of this protocol.
Response：
Thank you very much for your suggestion. Compared with cochrane systematic review in nonmalignant dust-related respiratory diseases, this study has the following characteristics. Firstly, the number of trials included is more. Secondly, the outcome indicators include not only exercise capacity and quality of life, but also pulmonary function indicators. Besides, the intervention of pulmonary rehabilitation is comprehensive, which include not only exercise training, but also health education, nutritional intervention, psychosocial support, etc.
Special thanks to you for your good comments.
VERSION 2 -REVIEW
REVIEWER
Arwel Jones
University of Lincoln, UK.
REVIEW RETURNED
11-Mar-2019
GENERAL COMMENTS
Thank you for the revised manuscript and responding to my previous comments. I have some minor issues which I do not think have been fully addressed and some comments on amendments you have made.
Protocol amendments: Firstly, I have a generic comment in regards to your response and revised manuscript. Given the timing of my initial review and stage of your protocol, some of my previous points were asking for clarification of your protocol (e.g. primary outcomes, GRADE approach, searching of unpublished literature) but subsequently you have made amendments. Hence, I would just echo a previous comment of mine. Please ensure you report these new (and any previous) protocol amendments in any report of the full review.
Patient and public involvement: Thank you for your honest report of patient and public involvement. As patients and public can become involved at any stage of a systematic review, I would delete "As this is a retrospective review of data that has already been collected" and leave as "Patients were not involved in development of the research question or the design of this study at this stage".
Population: I made a comment on your previous submission in regards to the population. You state that you will exclude studies including participants with complications, such as pulmonary heart disease, tuberculosis, and chronic pulmonary heart disease. My initial query was in regards to whether you will come across studies with mixed populations e.g. studies that include a population with numerous respiratory diseases. What was the plan to manage these studies? e.g. exclude or seek to extract data for your eligible population. Can I also check what you mean with your latest addition, are you saying you are going to exclude studies where participants have pulmonary heart disease, tuberculosis, and chronic pulmonary heart disease as co-morbidities? If so, will you contact authors to confirm this or rely on the full text of the paper? The reason I say this is that a study that includes patients with dust related ILD as a primary diagnosis may not detail this or at the very least I would not expect them to provide data for subgroups of patients (e.g. who do not have the conditions above). Sorry, but I think clarity is important here as understandably any decisions can have a large bearing on the evidence reviewed.
Data analysis: "There were no dichotomous outcomes in the outcome of this study, all of which were continuous outcomes. For continuous data, we will present the effect using mean differences (MD) with 95% confidence interval （Cis)." One of your outcomes, frequency of acute exacerbations, may be considered as a dichotomous outcome or as a rate. Please provide the measure of effect for acute exacerbations, which as a form of count data should not be synthesised as continuous measure.
Previous Cochrane Review: My final comment is in regards to a response made by the second reviewer. You present an argument as to the key differences between your review and a previous relevant Cochrane review. I recommend (and I think this what the second reviewer was suggesting) to refer to this at the end of your introduction. Currently, based on the end of your introduction, one may assume that the available literature has yet to be reviewed. In fact, in the discussion, you state it is first time that a study has looked at the efficacy and safety of PR in pneumoconiosis. Please update these sections to demonstrate how your review advances on the previous review of efficacy and safety. Note, this previous review also looked at pulmonary function and I would not agree that you are looking at safety as you have not reported any relevant outcomes for this.
REVIEWER
Leona Dowman
La Trobe University, Australia REVIEW RETURNED 25-Feb-2019 GENERAL COMMENTS This is a very nicely written protocol. Just some very minor revisions. There are still a few typos that need to be amended e.g the word and is missing before frequency as is a full stop in the same sentence on line 23 page 5. The word cochrane is repeated on line 36 page 6. The word both should be deleted in line 14 page 7. There is a full stop missing after pneumoconisos line 39 page 8. I would suggest a thorough check of the paper to ensure there are no more typo errors.
Line 4 page 7 does not make sense -There were no dichotomous outcomes in the outcome of this study, all of which were continuous outcome.
Is there a reason why the search ends on May 2018? That is more than 8 months from the present day. Would it not be better to do the search as close as possible to the current date. There could be relevant papers that were published in the last 8 months I am not convinced that you can state this is the first systematic review to investigate the effiicacy of PR for patients with pneumoconiosis since there is a cochrane review by Dale that includes this patient group. The dale cochrane review presented a dust related ILD (which was pneumoonicosis, asbestosis and silicosis) subgroup analysis for most outcomes. This review may provide more current data and a different and more specific analysis of PR in pneumonconiosis but arguably not the first.
VERSION 2 -AUTHOR RESPONSE
Thank you very much for your suggestion. Your comments are valuable and useful for modifying and perfecting our papers, and have important guiding significance for our research.
Please leave your comments for the authors below This is a very nicely written protocol. Just some very minor revisions. There are still a few typos that need to be amended e.g the word and is missing before frequency as is a full stop in the same sentence on line 23 page 5. The word cochrane is repeated on line 36 page 6. The word both should be deleted in line 14 page 7. There is a full stop missing after pneumoconisos line 39 page 8. I would suggest a thorough check of the paper to ensure there are no more typo errors.
Response：Thank you very much for your suggestion. We are very sorry for our incorrect writing. We have made correction according to your suggestion. (Page 5, 6, 7, 8) Line 4 page 7 does not make sense -There were no dichotomous outcomes in the outcome of this study, all of which were continuous outcome.
Is there a reason why the search ends on May 2018? That is more than 8 months from the present day. Would it not be better to do the search as close as possible to the current date. There could be relevant papers that were published in the last 8 months
Response：Thank you very much for your suggestion that will be of great help to us. The reason why the search ended in May 2018 was our manuscript began around May 2018. In fact, we will update our search timely to ensure all potentially eligible studies is included. We have made changes in the manuscript. (Page 5)
I am not convinced that you can state this is the first systematic review to investigate the efficacy of PR for patients with pneumoconiosis since there is a cochrane review by Dale that includes this patient group. The dale cochrane review presented a dust related ILD (which was pneumoconiosis, asbestosis and silicosis) subgroup analysis for most outcomes. This review may provide more current data and a different and more specific analysis of PR in pneumoconiosis but arguably not the first.
Response：Thank you very much for your suggestion. We are very sorry for inappropriate writing. Indeed, the efficacy of PR for patients with pneumoconiosis was already evaluated by meta-analysis of randomized controlled trials (RCTs) (Dale 2015). However, due to the inaccuracy of a small number of trials, the small number of participants and the indirectness of evidence, the quality of the evidence is low. The objective of this study is to provide a protocol of systematic review and metaanalysis to update PR for pneumoconiosis. This review will update the findings of Dale (2015) . Also, we plan to conduct subgroup analyses for different intervention forms to assess whether the treatment effects are different in different subgroups. We have made changes in the manuscript. (Page 8)
Please leave your comments for the authors below Thank you for the revised manuscript and responding to my previous comments. I have some minor issues which I do not think have been fully addressed and some comments on amendments you have made.
Response：Thank you very much for your suggestion, so that our manuscript has the opportunity to improve. We have deleted the extra content. according to your suggestion. (Page 7)
Population: I made a comment on your previous submission in regards to the population. You state that you will exclude studies including participants with complications, such as pulmonary heart disease, tuberculosis, and chronic pulmonary heart disease. My initial query was in regards to whether you will come across studies with mixed populations e.g. studies that include a population with numerous respiratory diseases. What was the plan to manage these studies? e.g. exclude or seek to extract data for your eligible population. Can I also check what you mean with your latest addition, are you saying you are going to exclude studies where participants have pulmonary heart disease, tuberculosis, and chronic pulmonary heart disease as co-morbidities? If so, will you contact authors to confirm this or rely on the full text of the paper? The reason I say this is that a study that includes patients with dust related ILD as a primary diagnosis may not detail this or at the very least. I would not expect them to provide data for sub-groups of patients (e.g. who do not have the conditions above). Sorry, but I think clarity is important here as understandably any decisions can have a large bearing on the evidence reviewed.
Response：Thank you very much for your suggestion that will be of great help to us. The purpose of this study was to evaluate the efficacy and safety of PR in pneumoconiosis patients. In the process of screening the study, we will come across studies with mixed populations e.g. studies that include a population with numerous respiratory diseases. Then, we will look at the full text to identify the participants of the study, whether have some complications, such as pulmonary heart disease, tuberculosis, and chronic respiratory failure. We will exclude studies including participants with complications. We believe that including patients with complications may affect the stability of the results. If a study includes patients with dust-related ILD diseases or dust-related respiratory diseases as a primary diagnosis, we also will first look at the full text to obtain the relevant data of pneumoconiosis. We will contact the authors to get data on pneumoconiosis and include it in metaanalysis, when we can't obtain relevant data by reading the full text.
Response：Thank you very much for your suggestion. I am very sorry that we did not describe the frequency of acute exacerbations clearly. Acute exacerbation is defined as characterized by deterioration of respiratory symptoms that exceed the range of daily changes and require active treatment (Hou 2018). The frequency of acute exacerbations is measured by the number of acute exacerbations, not by whether there is an acute exacerbation. Therefore, we believe that the frequency of acute exacerbation is a continuous outcomes.
Response：Thank you very much for your suggestion. Indeed, the efficacy of PR for patients with pneumoconiosis was already evaluated by meta-analysis of randomized controlled trials (RCTs) (Dale 2015) . The review findings also indicate that an exercise training programme is effective in improving exercise capacity and health-related quality of life in the short-term and at six months follow-up. However, due to the inaccuracy of a small number of trials, the small number of participants and the indirectness of evidence, the quality of the evidence is low. We remain unsure of these findings.
Larger, high quality trials are needed to determine the strength of these findings. The objective of this study is to provide a protocol of systematic review and meta-analysis to update PR for pneumoconiosis. This review will update the findings of Dale (2015) . There will be more trials included. Also, we plan to conduct subgroup analyses for different intervention forms to assess whether the treatment effects are different in different subgroups. We will also be concerned about the adverse effects reported by trials' authors. We have made changes in the manuscript. (Page 5, 8) Special thanks to you for your good comments.
VERSION 3 -REVIEW
REVIEWER
Arwel Jones University of Lincoln
REVIEW RETURNED
12-Apr-2019
GENERAL COMMENTS
Thank you for your revised manuscript. Forgive me for having to do this but I do not feel that two comments from my previous review have been addressed. I am not intending to be difficult, I've tried to raise points which I feel can provide the reader with the neccesary detail and hopefully help you at a later point when it comes to the final report of your systematic review (i.e. demonstrate transparency/reproducibility of the review). Hence, if not only for consistency, these are copied again below. As there were no response enclosed to my previous comments I'm unsure if you have missed these or rebut them.
